細菌人工染色体：プラス鎖RNAウイルスの研究のための機能ゲノミクスツール

Executive Industry Relevance

Cloning full-length cDNA of positive-strand RNA viruses into bacterial artificial chromosomes (BACs) addresses genome instability, enabling stable propagation of large viral genomes (>10 kb) for recombinant virus rescue. This approach provides a genetically defined platform for studying viral replication, pathogenesis, and vaccine development, reducing mechanistic uncertainty in early-stage antiviral and vaccine discovery programs. The method supports target validation and lead identification by generating infectious virus from defined genetic constructs.

Strategic Applications in Biopharma R&D

Early Discovery & Target Validation

• Scientific Value: Enables direct manipulation of viral genomic RNA to interrogate therapeutic hypotheses and clarify pathogenic mechanisms.
• Operational Value: Provides a stable genetic system for functional target validation, reducing false positives from plasmid instability.
• Predictive Value: Supports predictive confidence in target de-risking by generating recombinant viruses with defined genotypes for phenotypic screening.

Screening & Assay Development

• Scientific Value: Produces standardized infectious virus stocks for quantitative assay development and compound screening.
• Operational Value: Ensures batch-to-batch reproducibility of viral stocks, critical for reliable dose-response measurements in antiviral screening.
• Scalability: Facilitates preparation of large-scale virus stocks from BAC DNA for high-throughput screening campaigns.

Translational & Preclinical Research

• Translational Value: Maintains genetic fidelity from discovery through preclinical evaluation, supporting biomarker alignment and mechanism-of-action studies.
• De-risking: Reduces biological variability in efficacy and safety assessments by using isogenic virus stocks derived from BACs.
• Continuity: Enables seamless transition from mechanistic studies to vaccine candidate evaluation using the same genetic backbone.

Pipeline & Workflow Integration

The BAC-based reverse genetics workflow fits within the discovery continuum from target validation through lead identification to preclinical candidate evaluation, providing a reproducible source of infectious virus for downstream applications.

• Discovery Biology: Supports hypothesis testing and pathway clarification by enabling precise genetic modifications to viral genomes.
• Screening: Delivers standardized, quantifiable virus stocks for antiviral compound screening and resistance profiling.
• Analytics: Generates measurable outputs such as virus yield, plaque formation, and protein expression for comparative condition analysis.
• Translational Research: Connects genetic manipulation to phenotypic outcomes in preclinical models through consistent virus production.
• Enterprise Reuse: Establishes a reusable platform for studying multiple positive-strand RNA viruses, maximizing ROI on genetic engineering investments.

Operational & Enterprise Impact

• Scientific Value: Increases target validation confidence by eliminating confounding effects from unstable viral clones.
• Operational Value: Enhances reproducibility and scalability of virus production across teams and sites.
• Strategic Value: Improves go/no-go decision quality by reducing late-stage failures due to uncharacterized viral heterogeneity.
• Portfolio Impact: Enables risk-adjusted prioritization of antiviral and vaccine candidates based on mechanism-defined viral models.

Implementation Considerations

• Requires expertise in molecular cloning, bacterial culture, and RNA virology.
• Depends on access to ultracentrifugation, electrophoresis, and electroporation equipment.
• Necessitates standardization of BAC preparation and virus recovery protocols across laboratories.
• Involves biosafety containment (BSL-3 for JEV) and specialized training for handling positive-strand RNA viruses.
• Limited by the efficiency of in vitro RNA transcription and electroporation for virus recovery, which may vary by virus strain.

Biopharma FAQs